Gene Expression, Immunological Status and Metabolome in Glioma Patients

Monitoring and Analysis of Gene Expression, Immunological Status and Metabolome in Peripheral Blood Mononuclear Cells and Their Specific Subpopulations (CD4+ T Cells and CD56+ NK Cells) in Surgically Treated Glioma Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01525459

Enrollment

Registered

2012-02-03

Start date

2010-12-31

Completion date

2012-12-31

Last updated

2012-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Keywords

Glioma, PBMC subpopulations, Gene expression, Metabolomics, Immunological status, miRNA, Proteomics

Brief summary

Study on glioma patients treated with brain surgery is focusing on the analysis of their transcriptome expression profile measured in two immune cell populations, CD4+ T cells and CD56+ NK cells. The results of analysis will be compared to the reference data of healthy population. Furthermore, the metabolomic and immunological status will also be monitored and compared to healthy group reference data, before and after the surgery\*. With comparative crossomics analysis the investigators intend to possibly identify new diagnostic and prognostic biological markers for the relapse of the disease. The results are expected to convey a deeper insight into pathophysiology of the glioma as well as into the mechanisms of the current surgical therapy. \* The healthy reference data have been published in collaborative efforts of BTC, UMC and NIB (Gruden et al. 2012).

Interventions

PROCEDUREGlioma resection

Patients will be treated with the standard surgical therapy - glioma resection.

OTHERBlood sampling

Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* malignant glioma = glioblastoma (WHO IV) patients

Exclusion criteria

* pregnancy * metastases

Design outcomes

Primary

Measure	Time frame
Transcriptome profile of CD4+ T and CD56+ NK cells	within 10 days before surgery

Secondary

Measure	Time frame
Metabolite profiling in blood plasma samples	within 10 days before surgery, one day after surgery and once more within 10 days after surgery surgery
Lymphocyte subpopulation assessment in peripheral blood samples	within 10 days before surgery, one day after surgery and once more within 10 days after surgery
Antibody profiling in blood plasma samples	within 10 days before surgery, one day after surgery and once more within 10 days after surgery
miRNA profiling in blood plasma samples	within 10 days before surgery, one day after surgery and once more within 10 days after surgery surgery
Proteomic analysis of blood plasma samples	within 10 days before surgery, one day after surgery and once more within 10 days after surgery

Countries

Slovenia

Contacts

Primary ContactTamara Lah Turnšek, PhD

tamara.lah@nib.si+386-59-23-27-03

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026